U.S. News & World Report interviews Ana Maria Cuervo, M.D., Ph.D., and Nir Barzilai, M.D., about their aging research.  Drs. Cuervo and Barzilai are co-directors of Einstein’s Institute for Aging Research.


The New York Times interviews Dr. Nir Barzilai, M.D., about his upcoming clinical trial to determine if an existing FDA-approved drug can extend health span. Dr. Barzilai and his collaborators at the American Federation for Aging Research will investigate if metformin, a cheap and commonly used medication to treat type 2 diabetes, can delay the onset of several age-related diseases. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.

More coverage on this story

The Washington Post


National Geographic highlights the leadership role Nir Barzilai, M.D., is taking in a clinical trial to determine if a common diabetes drug can delay aging. Dr. Barzilai notes that the goal of the Targeting Aging with Metformin (TAME) study is not to find the “fountain of youth,” but to extend the number of healthy, active years humans can enjoy. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.

More coverage on this story

Forbes
Fox News
PIX 11
National Post (Canada)
The Telegraph
Newsweek


Science profiles Nir Barzilai, M.D., and the ambitious proposed clinical trial he is leading that would evaluate if metformin can delay aging in humans. The article details his meeting with FDA, which was supportive of the approach, and the key roles his collaborators at the American Federation for Aging Research are playing in the effort. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.


Scientific American interviews Nir Barzilai, M.D., about latest research advances for slowing or delaying the aging process in humans. Dr. Barzilai, who conducts longevity research with centenarians, notes his “superagers” tend to have a significant delay in the onset of age-related diseases and stay healthier longer. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein and attending physician at Montefiore Medical Center.


Nature features Nir Barzilai, M.D., and his proposed TAME study, which will investigate if the widely used diabetes drug metformin can delay aging. Dr. Barzilai notes that he and his colleagues are not seeking the “fountain of youth,” but rather an effective means to extend the number of healthy years an individual has, or “healthspan.” Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein and attending physician at Montefiore Medical Center.


The Scientist interviews Nir Barzilai, M.D., and Evris Gavathiotis, Ph.D., about their success in pursuing private funding in the face of federal funding cuts. Drs. Barzilai and Gavathiotis share how they identified and pursued alternative funding sources and how it has helped advance their research.  Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein and attending physician at Montefiore Medical Center. Dr. Gavathiotis is assistant professor of biochemistry and of medicine.


The New York Times references Einstein’s centenarian studies and Nir Barzilai, M.D., in an obituary on 109-year old Irving Kahn. Kahn, considered the oldest active Wall Street investor before his death, was a participant in Dr. Barzilai’s studies at Einstein’s Institute of Aging Research. He was also profiled as part of Einstein’s Longevity Genes Project video series. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein and attending physician at Montefiore Medical Center.


Bloomberg News interviews Nir Barzilai, M.D., about Novartis’ efforts to develop FDA-approved drug rapamycin as an anti-aging, preventative therapy. It was long believed that rapamycin suppressed the immune response, rendering it unsuitable for long-term use in older adults. However, Dr. Barzilai notes that a recent “watershed” moment occurred when new research found it merely modulated the immune response in humans, clearing the way for more research. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein and attending physician at Montefiore Medical Center.


The New York Times and NPR feature Nir Barzilai, M.D., and one of his centenarian study participants in a joint article on aging. Dr. Barzilai notes that as a scientist, his goal isn’t to help people live longer, but to live healthier. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director the Institute for Aging Research at Einstein and attending physician at Montefiore Medical Center.


Wall Street Journal features new research by Nir Barzilai, M.D. that found lower levels of growth hormone are associated with extended lifespan in centenarians. Concerns about the dangers of using human growth hormone (HGH) as an anti-aging agent—a growing $4 billion industry—are increasing. Dr. Barzilai notes hormones that might have some beneficial effect for children with stunted growth may have a negative effect on aging adults. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of Einstein's Institute for Aging Research.


NPR interviews Nir Barzilai, M.D., about a new study that showed men who adopted healthier lifestyles had longer telomeres. Telomeres protect the tips of chromosomes and are associated with lower risk for many chronic diseases and longer lifespan. Dr. Barzilai notes that the study doesn't answer the fundamental question of causation — whether someone is healthy because they have longer telomeres or someone's telomeres become longer because they are healthy. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of Einstein's Institute for Aging Research.


Geoffrey Kabat, Ph.D., interviews Nir Barzilai, M.D., in a Forbes article about his aging research and the genetic determinants of healthy longevity. Dr. Kabat reports that Dr. Barzilai’s lab has discovered several genetic variants that appear to extend human health-span, one of which is the basis of a drug currently in phase III clinical trials. Dr. Kabat is a senior epidemiologist at Einstein. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of Einstein’s Institute for Aging Research.


Several Einstein faculty members and their research are featured in a National Geographic cover story on the potential genetic roots of longevity.  Harry Ostrer, M.D., Roee Holtzer, Ph.D., and Nir Barzilai, M.D., are quoted, providing insight into the some likely genetic factors of healthy aging and the varied physiological and behavioral outcomes of these factors. Ongoing epigenetic investigations by Francine Einstein, M.D. and John Greally, M.B.B.Ch, Ph.D., are also highlighted, as is Dr. Holtzer’s collaborator Joe Verghese, M.B.B.S.


Richard Dawkins interviews Nir Bazilai, M.D., on U.K. TV about the trade-off between living longer and having fewer children. (Segment begins at 28:15) Mr. Dawkins, an English evolutionary biologist and author, also interviews Irving Kahn, a participant in Dr. Barzilai's The Longevity Genes Project, in his new series titled "Sex, Death and the Meaning of Life." Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research.